Just in the footnote of the Key dates for AGM Announcement
A mid-cycle review for the product has been successfully completed by FDA in 1Q 2023, which subject to other information that may be required
by FDA, remains on track for approval targeted for the end of September 2023.
Sofpironium Bromide is positioned to be a leading first line and second line therapy and potentially represents a
safe and effective new option for patients.
Bot Chart, page-7921
-
- There are more pages in this discussion • 7,970 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
33.5¢ |
Change
-0.005(1.47%) |
Mkt cap ! $608.8M | |||
| Open | High | Low | Value | Volume |
| 33.5¢ | 34.3¢ | 32.5¢ | $1.200M | 3.588M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 349093 | 33.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.5¢ | 25403 | 5 |
View Market Depth
| Last trade - 16.10pm 11/11/2024 (20 minute delay) ? |
| BOT (ASX) Chart |